Physiologic study demonstrates MIB-626 increases NAD and improves cardiometabolic markers in overweight older adults, suggesting potential for larger clinical trials.
MIB-626 administration in overweight or obese, middle-aged and older adults safely increased circulating NAD levels, and significantly reduced total LDL and non-HDL cholesterol, body weight, and diastolic blood pressure. These data provide the rationale for larger trials to assess the efficacy of NAD augmentation in improving cardiometabolic outcomes in older adults.
No takes yet. Share an insight, caveat, or question.
Pencina et al. (2023) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: